Search results
21 mar 2023 · Overview of manufacturing of allogenic ‘off‐the‐shelf’ Epstein–Barr virus (EBV)‐specific T‐cell therapy for the treatment of multiple sclerosis (MS) patients. Peripheral blood mononuclear cells from healthy EBV seropositive individuals are stimulated with a recombinant replication‐deficient adenovirus encoding EBV antigens.
11 lis 2018 · An open-label phase I trial was designed to treat 5 patients with secondary progressive MS and 5 patients with primary progressive MS with 4 escalating doses of in vitro–expanded autologous EBV-specific T cells targeting EBV nuclear antigen 1, latent membrane protein 1 (LMP1), and LMP2A.
11 mar 2022 · Epstein-Barr virus (EBV) is a putative trigger for multiple sclerosis (MS). Bjornevik et al. utilized longitudinal analysis of 10 million adults to strongly link MS to EBV infection1 and Lanz et al. identified clonally expanded B cells in MS that bind EBV EBNA1 and GlialCam.2
The central role of Epstein-Barr virus in causing multiple sclerosis is examined to understand how it triggers the disease and presents new opportunities for treatment.
7 lut 2023 · Large-scale genomic sequencing of EBV to search for pathogenic EBV variants associated with multiple sclerosis, and the study of the interactions between EBV and human genetics, will lead to a better understanding of EBV-induced disease mechanisms.
21 gru 2023 · Multiple sclerosis (MS) affects the brain and various nerves, including the peripheral nerve system, with localized damage to the myelin sheath around neurons reducing nerve function. MS is an autoimmune disease that has long been suspected to be associated with Epstein-Barr virus (EBV) infection.
17 gru 2019 · The idea that a virus may play a role in the development of MS has a long history and is supported mostly by studies demonstrating a link between B cell-tropic Epstein–Barr virus (EBV) and disease onset. Efforts to develop antiviral strategies for treating MS are underway.
